Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer

Journal of Urology

Volumn 179, Issue 2, 2008, Pages 485-490

  Naito, Seiji ^a   Koga, Hirofumi ^a   Yamaguchi, Akito ^c   Fujimoto, Naohiro ^e   Hasui, Yoshihiro ^g   Kuramoto, Hiroshi ^f   Iguchi, Atsushi ^d   Kinukawa, Naoko ^b  

^a Department of Urology ^*  (Japan)

^b Medical Information on Science   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^f Moji Rousai Hospital   (Japan)

^g UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Bladder; Bladder neoplasms; Epirubicin; Lactobacillus casei; Neoplasm recurrence, local

Indexed keywords

EPIRUBICIN; LACTOBACILLUS CASEI EXTRACT; ANTINEOPLASTIC ANTIBIOTIC; PROBIOTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOLOGY; HUMAN; LACTOBACILLUS CASEI; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION; BLADDER TUMOR; COHORT ANALYSIS; CYSTOSCOPY; DISEASE FREE SURVIVAL; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PATHOLOGY; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; COHORT STUDIES; COMBINED MODALITY THERAPY; CYSTOSCOPY; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; LACTOBACILLUS CASEI; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROBIOTICS; URINARY BLADDER NEOPLASMS;

EID: 38849086869     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.09.031     Document Type: Article

References (17)

1. Jone JS and Campbell SC: Non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: Campbell-Walsh Urology, 9th ed. Edited by AJ Wein, LR Kavoussi, AC Novick, AW Partin and CA Peters. Philadelphia: WB Saunders Co 2007; pp 2447-2467.
2. Hinotsu S, Akaza H, Ohashi Y and Kotake T: Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999;86:1818.
3. Nilsson S, Ragnhammar P, Glimelius B and Nygren P: Swedish Council of Technology Assessment in Health Care: a systematic overview of Chemotherapy effects in urothelial bladder cancer. SBU-group. Acta Oncol 2001;40:371.
4. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991;325:1205.
5. Kato I, Endo K and Yokokura T: Effects of oral administration of Lactobacillus casei on antitumor responses induced by tumor resection in mice. Int J Immunopharmacol 1994;16:29.
6. Takahashi T, Kushiro A, Nomoto K, Uchida K, Morotomi M, Yokokura T et al: Antitumor effects of the intravesical instillation of heat killed cells of the Lactobacillus casei strain Shirota on the murine orthotopic bladder tumor MBT-2. J Urol 2001;166:2506.
7. Aso Y and Akazan H: Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group. Urol Int 1992;49:125.
8. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K and Naito S: Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol 1995;27:104.
9. Holford TR: Life tables with concomitant information. Biometrics 1976;32:587.
10. Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S and Ashamallah A: Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 1997;79:731.
11. Okamura K, Kinukawa T, Tsumura Y, Otani T, Itoh H, Kobayashi H et al: A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol 1998;33:285.
12. Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S et al: A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 2004;171:153.
13. Fuller R: Probiotics in man and animals. J Appl Bacteriol 1989;66:365.
14. Lee YK, Nomoto K, Salminen S and Gorbach SL: Probiotic microorganisms. In: Handbook of Probiotics. Edited by YK Lee, K Nomoto, S Salminen and SL Gorbach. New York: John Wiley and Sons 1999; pp 4-17.
15. Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyanaga N et al: Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int 2002;68:273.
16. Hayatsu H and Hayatsu T: Suppressing effect of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. Cancer Lett 1993;73:173.
17. Nagao F, Nakayama M, Muto T and Okumura K: Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the immune system in healthy human subjects. Biosci Biotechnol Biochem 2000;64:2706.